Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyal-Joint
- Development stage
- Preclinical
- Lead developer
- Bioiberica
- Administration
- Oral
01
Overview
Hyal-Joint is a branded, natural extract derived from chicken combs, containing a high concentration (60%) of hyaluronic acid, along with collagen and other glycosaminoglycans. [10] It is marketed as an oral dietary supplement to support joint health, particularly for individuals with osteoarthritis. [4] Clinical evidence suggests that daily supplementation with Hyal-Joint can improve markers of quality of life, reduce joint pain, and enhance physical function in adults with knee osteoarthritis. [4, 18] Its proposed mechanism involves lubricating joints, maintaining the viscoelasticity of synovial fluid, and stimulating the body's own production of hyaluronic acid. [1, 2]
- Brand names
- Hyal-Joint
- Other names
- chicken comb extract
02
Targets
CD44 (CD44 antigen)HMMR
Beyond the preview
Go deeper on Hyal-Joint.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyal-Joint.